Please note, today's event is being recorded. I would now like to turn the conference over to Mark Stolper, Chief Financial Officer. Please go ahead, sir. Thank you. Good morning, ladies and gentlemen, and thank you for joining Dr. Howard Berger and me today to discuss RadNet's second quarter 2023 financial results. Before we begin today, we'd like to remind everyone of the safe harbor statement under the Private Securities Litigation Reform Act of 1995. This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning anticipated future financial and operating performance, RadNet's ability to continue to grow the business by generating patient referrals and contracts with radiology practices, recruiting and retaining technologists, receiving third-party reimbursement for diagnostic imaging services, successfully integrating acquired operations, generating revenue and Adjusted EBITDA for the acquired operations as estimated, among others, are forward-looking statements within the meaning of the safe harbor. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause RadNet's actual results to differ materially from the statements contained herein. These risks and uncertainties include those risks set forth in RadNet's reports filed with the SEC from time to time, including RadNet's annual report on Form 10-K for the year ended December 31st, 2022. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date it is made. RadNet undertakes no obligation to publicly update any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. And with that, I'd like to turn the call over to Dr. Berger. Thank you, Mark. Good morning, everyone, and thank you for joining us today. On today's call, Mark and I plan to provide you with highlights from our second quarter 2023 results, give you more insight into factors which affected this performance, and discuss our future strategy. After our prepared remarks, we will open the call to your questions. I'd like to thank all of you for your interest in our company and for dedicating a portion of your day to participate in our conference call this morning. I am very pleased with our performance in the second quarter. It was the strongest quarter in our company's history, with record revenue and Adjusted EBITDA. Relative to last year's second quarter, our core imaging center segment revenue increased 13.8%, and imaging center Adjusted EBITDA increased 14.7%. This performance was driven in part by heavy demand in virtually all of our markets. Aggregate procedural volumes increased 11.4%, and same-center procedural volumes increased 7.1% compared with the second quarter of 2022. This heavy demand is being driven by a number of factors that we have highlighted in recent quarters, which we believe will continue to create strong growth for years to come. First, within the healthcare delivery system, there is a growing focus on preventative, non-invasive medicine, with keen interest in the earlier and more accurate detection of diseases. As managed care grows, risk-based provider models become more common, and population health screening becomes more prevalent, diagnostic imaging will grow in its importance. Second, as the population expands and ages, diagnostic imaging is used with greater frequency. In fact, Medicare lives utilizing imaging two to three times more often than younger commercial lives. Third, technology in our industry continues to evolve and improve, creating additional medical indications for ordering diagnostic imaging tests. Advances in MRI technology and post-processing software have shortened scanning times, increased throughput and capacity, and improved imaging quality. New contrast materials and radioactive pharmaceuticals are driving novel applications such as PSMA, or prostate-specific membrane antigen, PET scans, and Alzheimer's imaging. While these factors explain the steady growth in our industry, there is also a market shift taking place within diagnostic imaging that is also working in RadNet's favor. Increasingly, patient volumes are being directed away from expensive, hospital-based imaging facilities towards more cost-effective ambulatory outpatient settings. Freestanding outpatient centers offer more convenient and lower-cost services that are preferred by patients, referring physicians, and payers. We believe these favorable trends will continue to help drive our future same-center performance and present growth opportunities for years to come. To address these trends, we've opened 1 new facility, and we currently have 12 de novo facilities in various stages of development, which will open for operation in the second half of 2023 and throughout 2024. These facilities are located in markets where we have patient backlogs, require additional capacity, or where we currently lack access points to service patient populations in need. While these projects require us to make capital investments above our normal spending, we are confident these centers will be material contributors to our long-term performance and growth. While the labor market remains challenging, we have been more successful in filling open positions and have been reducing our reliance on expensive temporary staffing services and overtime hours of our existing team members. We continue our efforts to grow our hospital and health system partnership initiatives. Currently, 120 of our 363 centers, or 33%, are held within health system partnerships. Our partnerships are some of the largest and most successful systems in our geographies, including RWJBarnabas, MemorialCare, Dignity Health, LifeBridge, University of Maryland Medical System, the Adventist Health System, Cedars-Sinai, and others. These other health systems are seeking solutions for long-term strategies around outpatient imaging and have recognized that cost-effective and efficient freestanding imaging centers will continue to capture market share from hospitals as payers and patients migrate their site of care towards lower cost, high-quality solutions. We expect by year-end, our JV centers could represent closer to 40% of our total center account. Our hospital and health system partners have been instrumental in increasing our procedural volumes through their relationships with physician partners. Additionally, our JV partners are helpful in providing support, if needed, in establishing long-term, equitable outpatient reimbursement rates for our services. As a result of the strong performance in the first half of this year and the confidence we are feeling for the remainder of the 2023 period, we have elected to increase key financial guidance levels in our core imaging center operating segment for 2023. Mark, in his prepared remarks, will review the increases we made to our revenue and Adjusted EBITDA guidance levels upon releasing our financial results this morning. Lastly, we continue to make progress with our AI and digital health initiatives. You may have seen a recent press release announcing two additions to our executive team, who will be focused on driving growth in our digital health businesses to include both clinical and generative AI opportunities, as well as opportunities in our eRAD imaging informatics and related software businesses. Shyam Sokka and Sanjog Misra will be focused on commercialization, partnerships, product development, and operations in our digital health platform. While they assist us with continued progress of DeepHealth, Aidence, and Quantib, Shyam and Sanjog will also be launching a number of initiatives in generative AI, designed to improve efficiency and lower cost of many of our core business processes, such as contact centers, scheduling, insurance verification, front office functions, reporting tools, revenue cycle, and many more. Generative AI should be as transformative to the core functions of our imaging center business as clinical or predictive AI will be to the delivery of our professional radiology services and population health screening. In the coming quarters, we will share the initiatives that we are undertaking, a number of which have been prioritized to help us address the challenges of the current labor market. I'm also pleased to announce that Dr. Greg Sorenson, the founder of DeepHealth, the first AI company we purchased over three years ago, has assumed the role of Chief Science Officer and has joined the Board of Directors of RadNet. The investments we are making in digital health technology and personnel underscore our commitment to our digital health initiatives and highlight their growing importance to RadNet's future strategic direction and priorities. We are experiencing strong growth with our digital health platform. In the first 6 months of this year, our AI revenue grew 109% from last year's same period, driven predominantly by the launch of our Enhanced Breast Cancer Detection, EBCD mammography offering, which we continue to implement across our networks. We expect this growth to accelerate in the second half of this year as we expand EBCD to more of our women's centers throughout our markets, particularly within our West Coast operations. The results of the program and the feedback we are receiving from our patients, referring physicians, and hospital partners have been excellent. Since the inception of the EBCD program, we have diagnosed over 450 breast cancers that, without the intervention of artificial intelligence, might have gone otherwise undetected. Detecting cancer sooner allows for better patient outcomes through earlier treatment and intervention and reduces costs to the healthcare system. Furthermore, we are reducing the callback rates for patients through the use of AI by being more definitive with the initial screening exam. We currently are experiencing approximately 30% enrollment in the EBCD mammography screening program and believe we will see greater uptake as we improve communicating and marketing the benefits to our patients and their referring physicians. Finally, I would like to comment on RadNet's liquidity position and financial leverage. On June 16th, we completed an equity offering where we raised $246 million of net proceeds to deleverage our balance sheet and position us to accelerate growth. This offering, along with strong operating performance, re-resulted in a net debt to Adjusted EBITDA ratio of approximately 2x at quarter end. We currently have the lowest leverage and strongest liquidity position in our company's history. As of June 30th, we had $357 million of cash on our balance sheet, and we're undrawn on our $195 million revolving line of credit. Our days sales outstanding, DSOs, at June was 35.4 days, which we believe to be one of the best in the industry. While we are committed to growing and expanding our business, we will also continue to follow a methodical and disciplined approach to managing our financial leverage. Our low leverage, lower cost of capital, and strong liquidity, relative to many of our other industry operators, position us to capitalize on acquisition opportunities and other business opportunities where capitalization is advantageous. We remain patient and disciplined in our approach to acquisitions, focused first on our core markets, where we bring unique synergies and cost savings. At this time, I'd like to turn the call back over to Mark to discuss some of the highlights of our second quarter 2023 performance. When he is finished, I will make some closing remarks. Thank you, Howard. I'm now going to briefly review our second quarter 2023 performance and attempt to highlight what I believe to be some material items. I will also give some further explanation of certain items in our financial statements, as well as provide some insights into some of the metrics that drove our second quarter performance. I will also provide an update to 2023 financial guidance levels, which were released in conjunction with our 2022 year-end results in March, and which we amended in May upon releasing our first quarter financial results. In my discussion, I will use the term Adjusted EBITDA, which is a non-GAAP financial measure. The company defines Adjusted EBITDA as earnings before interest, taxes, depreciation, and amortization, and excludes losses or gains on the disposal of equipment, other income or loss, loss on debt extinguishments, and non-cash equity compensation. Adjusted EBITDA includes equity and earnings of unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taking place during the period. A full quantitative reconciliation of Adjusted EBITDA to net income or loss attributable to RadNet, Inc. common shareholders is included in our earnings release. With that said, I'd now like to review our second quarter 2023 results. For the second quarter of 2023, RadNet reported revenue from its imaging centers reporting segment of $401.3 million and Adjusted EBITDA of $63.7 million, which exclude revenue and losses from the AI reporting segment. As compared with last year's second quarter, RadNet revenue increased $48.5 million, or 13.8%, and Adjusted EBITDA increased $8.2 million or 14.7%. Including our AI reporting segment, revenue was $403.7 million in the second quarter of 2023, an increase of 13.9% from $354.4 million in last year's second quarter. Including the losses of the AI reporting segment, Adjusted EBITDA was $60.4 million in the second quarter of 2023, and $51.3 million in the second quarter of 2022, an increase of 17.7%. For the second quarter of 2023, RadNet reported net income of $8.4 million, as compared with $7.9 million for the second quarter of 2022. Diluted net income per share for the second quarter of 2023 was $0.12, compared with a diluted net income per share of $0.13 in the second quarter of 2022, based upon a weighted average number of diluted shares outstanding of 60.9 million shares in 2023 and 57 million shares in 2022. There were a number of unusual or one-time items impacting the second quarter, including the following: $4.2 million of non-cash gain from interest rate swaps, $1 million expense related to the change in valuation of contingent consideration related to completed acquisitions, $759,000 of expense related to leases for our de novo facilities under construction that have yet to open their operations, and $8.7 million of pre-tax losses related to our AI reporting segment. Adjusting for the above items, adjusted earnings from the imaging centers reporting segment was $14.9 million, and diluted adjusted earnings per share was $0.24 during the second quarter of 2023. This compares with adjusted earnings of $8.6 million and diluted adjusted earnings per share of $0.15 during the second quarter of 2022. Also affecting net income in the second quarter of 2023 were certain non-cash expenses and unusual items, including the following: $4.9 million of non-cash employee stock compensation expense, resulting from the vesting of certain options and restricted stock, $1.9 million of severance paid in connection with headcount reductions related to cost savings initiatives, $77,000 of disposal of certain capital equipment, and $748,000 of non-cash amortization of deferred financing costs and loan discounts related to financing fees as part of our existing credit facilities. For the second quarter of 2023, as compared with the prior year's second quarter, MRI volume increased 11.8%, CT volume increased 11.3%, and PET CT volume increased 18.3%. Overall volume, taking into account routine imaging exams inclusive of X-ray, ultrasound, mammography, and all other exams, increased 11.4% over the prior year's second quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2023 and 2022, MRI volume increased 7.3%, CT volume increased 6.3%, and PET CT volume increased 18.8%. Overall, same-center volume, taking into account all routine imaging exams, increased 7.1% over the prior year's same quarter. In the second quarter of 2023, we performed 2,551,382 total procedures. The procedures were consistent with our multimodality approach, whereby 75% of all the work we did by volume was from routine imaging. Our procedures in the second quarter of 2023 were as follows: 387,619 MRIs, as compared with 346,598 MRIs in the second quarter of 2022. 235,138 CTs, as compared with 211,221 CTs in the second quarter of 2022. 15,036 PET CTs, as compared with 12,710 PET CTs in the second quarter of 2022, 1,913,589 routine imaging exams, as compared with 1,719,647 of all these exams in the second quarter of 2022. Overall, GAAP interest expense for the second quarter of 2023 was $16 million. This compares with GAAP interest expense in the second quarter of 2021 of $11.4 million. Higher interest expense is predominantly the result of the upsized New Jersey Imaging Network credit facility, completed in October of last year in conjunction with NJN's acquisition of Montclair Radiology. Cash paid for interest during the period, which excludes non-cash deferred financing expense and accrued interest, was $17.8 million. Cash paid for interest, net of interest earned on our cash balance and interest rate swap payments received, was $12.4 million for the three-month period ended June thirtieth, 2023, and $29.9 million for that same period last year. With regards to our balance sheet, as of June 30th, unadjusted for bond and term loan discounts, we had $518.9 million of net debt, which is our total debt at par value, less our cash balance. This compares with $662.1 million of net debt at June 30th, 2022. Note that this debt balance includes New Jersey Imaging Network's debt of $146.3 million, for which RadNet is neither a borrower nor guarantor. As of June 30th, 2023, we were undrawn on our $195 million revolving line of credit and had a cash balance of $357 million. At June 30, 2023, our accounts receivable balance was $174.5 million, an increase of $8.1 million from year-end 2022. The increase in accounts receivable is mainly the result of the significant increase in our procedural volumes over the last quarter. Our days sales outstanding, or DSO, remains near the lowest levels in our company's history at 35.4 days as of June 30, 2023. Through June 30, 2023, we had cash capital expenditures, net of asset dispositions and sale of imaging center assets and joint venture interests of $86.9 million. This excludes $8.4 million of cash capital expenditures at our New Jersey Imaging Network joint venture. At this time, I'd like to update and revise our 2023 fiscal year guidance levels, which we released in conjunction with our fourth quarter and year-end 2022 results, and amended after reporting our first quarter 2023 financial results. For total net revenue, we have increased our guidance range by $25 million at the low end and $10 million at the high end, to $1.575 billion-$1.610 billion. For Adjusted EBITDA, we've increased both the low end and the high end of our guidance by $7 million to $232 million-$242 million. We have left our capital expenditure, cash interest expense, and free cash flow guidance levels unchanged, as amended, after the first quarter results. For the artificial intelligence segment, due to the delay that Dr. Berger spoke about in our implementation of that program, we have lowered the guidance, the revenue guidance by $5 million, both at the low end and the high end, to $11 million-$13 million. Our Adjusted EBITDA loss projection for the year has increased by $2 million at both the low end and the high end, to $11 million-$13 million, loss for the year. In our core imaging center reporting segment, we have increased our guidance ranges for revenue and Adjusted EBITDA to reflect the strong financial results of the first half of 2023, as compared with our initial budget. As Dr. Berger mentioned, we've lowered our guidance ranges for revenue and Adjusted EBITDA for the AI segment, and we have been refining the EBCD program and have been testing different levels of pricing, various service offerings, new marketing collateral, local market sales, and marketing strategies. We estimate that this optimization process has resulted in a 90 day- 120 day delay in the progress of the program. Though the new revenue guidance levels fall short of our original estimate, estimates, it represents almost a tripling of our business from 2022 levels. We remain incredibly excited about the growth in AI. We continue to believe that we can break even in the AI segment before the end of 2024. I'll now take a few minutes to give you an update on 2024 reimbursement and discuss what we know with regards to 2024 anticipated Medicare rates. As a reminder, Medicare represents about two to... About 22% of our business mix. With respect to Medicare reimbursement, several weeks ago, we received a matrix for proposed rates by CPT code, which is typical as part of the Physician Fee Schedule proposal that is released about this time every year. We have completed an initial analysis and compared those rates to 2023 rates. We volume weight our analysis using expected 2024 procedural volumes. As you may recall, three years ago, CMS moved forward with increased reimbursement for Evaluation and Management CPT codes, which favor certain physician specialties that regularly bill for these services, particularly primary care doctors. CMS proposed doing so with budget neutrality, meaning that it proposed to reallocate reimbursement from physicians who rarely bill for E&M codes, to physicians who regularly bill for these codes. As a result, radiology and most other specialties experienced cuts in reimbursement during 2021, 2022, and 2023. Cuts meant to be phased in over a several-year period. The cuts we faced in 2023 were substantially mitigated by legislation that was passed at the end of last year as part of the Consolidated Appropriations Act. In this year's proposed ruling governing 2024 reimbursement, Medicare appears to effectively be phasing in any remainder of the E&M code related cut avoided last year as a result of the Consolidated Appropriations Act. The cut proposed for 2024 results from a decrease in the conversion factor in the Medicare fee schedule by about 3.4%, from $33.89 to $32.75, along with certain minor changes to the RVUs, the relative value units, of certain radiology CPT codes. Our initial analysis of the proposal for next year implies that RadNet, on roughly $1.6 billion in revenue, would face an approximately $7 million-$9 million revenue hit in 2024 from its Medicare business. Because the proposed decrease in the conversion factor affects all physicians, not just radiologists, there are many lobbying groups from the various medical specialties aggressively opposing the cut, including radiology's two main lobbying forces, the Association for Quality Imaging, or AQI, and the American College of Radiology, the ACR. At this time, our experts believe there is a high probability that the final rule to be released in November will be less severe than the current proposal as a result of congressional action that could take place later this year, similar to what happened last year. In November, during our third quarter financial results call, we hope to have more of an update to give you about this matter. While the $7 million-$9 million cut to RadNet's revenue next year is not insignificant, we have reimbursement increases completed or scheduled from capitated and commercial payers that will fully mitigate this Medicare reduction, which should go into effect in the currently proposed period. I'd now like to turn the call back to Dr. Berger, who will make some closing remarks. Thank you, Mark. Technology has always been a driver for change in our industry. This appears to be truer today than ever before. Artificial intelligence, both clinical and generative, is in its nascent stage within the field of radiology. Everything that we do today will be impacted by technology innovation and artificial intelligence in the coming years. Our business is an information technology business. Almost every process we perform, including collection of patient informations, scheduling, pre-authorization, insurance verification, creation of radiology reports, billing and collecting, medical coding, and processing of patient payments, can be enhanced by data algorithms and management tools. Artificial intelligence and informatics either already play or will play important roles in all of these business processes. RadNet has always been on the leading edge of technology, which has been a key to our success. In the past, we have both adopted solutions from others that benefited our business and created our own solutions in areas where we felt were imperative for us to control. This philosophy has not changed. In 2010, we began a journey to design our own Radiology Information System and image management system, which has become core to our data workflow. Much of what we do at the operating level and the efficiencies we have created in operating our 363 centers have been the result of our ability to control our IT infrastructure. As we move into the next generation of innovation, driven primarily by AI, we see even more opportunity to bring efficiencies, cost savings, and improved margins to RadNet through investments in our digital health initiatives. As demonstrated by our second quarter results, our core operating business is healthy and growing, supported by heavy and expanding procedural volumes. The next stage of RadNet's growth and development will be to bring these technological solutions to our business and to the broader radiology marketplace that make servicing this accelerating demand possible. I believe we have assembled many of the components, including the management talent, to take our business and industry to the next level of innovation, elevating radiology and our diagnostic capabilities to an even more important and critical role in healthcare delivery. We're excited to keep our stakeholders informed of our progress in these areas, while continuing to execute on driving growth in our core business through a focus on same-center performance, hospital and health system partnerships, tuck-in acquisitions, and de novo expansion. Operator, we are now ready for the question and answer portion of the call. Thank you. If you would like to ask a question, please press star then one on your telephone keypad. If you are using a speakerphone, we ask that you please pick up your handset before pressing the keys. To withdraw your question, please press star then two. We will pause momentarily to assemble our roster. Today's first question comes from Brian Tanquilut with Jefferies. Please go ahead. Hey, good morning, guys. I guess my first question for Howard and maybe Mark, too, you know, obviously the core business is strong and volume performance was, you know, really compelling. Just curious how you're thinking about the sustainability of, you know, strong demand trends and your ability to maintain, you know, healthy organic growth rates going forward? Good morning, Brian. Thank you. I think the key to sustaining, you know, our growth is really the investment that I've talked about in our digital health platform. The advent of generative AI, as well as the faster and easier development of new algorithms, will allow us to transform all of the processes that we use to operate our imaging centers considerably more efficiently, and with less dependence on the labor issues that we currently face, much as everybody in healthcare, and for that matter, the general economy. We expect the growth in the imaging sector of our business to continue to grow, but that the ability for us to scale up-... Perform the necessary tasks and demands that we have, will be imperative for us to use these tools that can create these efficiency and lessen our dependence on an already overstretched or stretched labor market. As we move into the latter part of this year, and certainly by the first quarter, we'll be able to perhaps talk a little bit more specifically about these initiatives. As we demonstrated in the press release that we made about a week or so ago, with the new executives added to this team, we feel that we are in an excellent position to drive this transformational change and control the processes that have allowed us to operate all 363 of our centers on a single platform, regardless of what market that we're in. While I like to think that we can be proud of what we've achieved to this point, I think the best is yet to come in terms of the technological innovation and transformation which radiology and imaging are probably better suited for than virtually any other specialty in the healthcare industry. Brian, I'll just add one, one other thing here. Another key to our continued growth and success is, you know, the ability to increase our capacity. You know, the 12 de novo centers that we have currently under construction, I think five of which will open by year-end or should open by year-end, the other seven sometime in 2024, will also be instrumental in our ability to create the capacity that we need to better service the heavy demand that we have right now in virtually all of our markets, where we're experiencing, you know, significant backlogs. Which is obviously a high-class problem, but, you know, one that, you know, is, is still indeed a problem, you know, as we try to get, you know, patients into our centers, you know, expeditiously and try to provide, you know, great service to our referring physician community. I think that the de novo strategy, and driving that level of capacity, in addition to the technology advances that Dr. Berger talked about, as well as, some additional technology that, that we've licensed that allow for shorter scan times for MRI scanning with post-processing software, that, you know, allows for greater throughput and, and, and obviously greater capacity at our center. All these things, you know, are important to continue to, to be able to grow the, you know, like, like we have been. The demand for imaging services is there, and that's, that's, that's clear in all of our markets. Understand. I appreciate that. Then I guess my second question: as we think about AI, and I, I understand, you know, the, the reasons for the delay or, you know, the pushing, some of the targets out, I guess two, two questions. As I think about, you know, Mark, you said you think you'll still hit break even, you know, by, by the end of 2024. I mean, maybe you can remind us, how does that compare to your original outlook for the business? Then second, maybe taking a step, step back, how are you thinking about, you know, or where does your confidence come from in your ability to get the AI side of the business where you want it to be, in the timeframe that you've, you've outlined? Hi, Brian. I'll, I'll take that one, and Mark can fill in if he thinks I've missed anything, like you did so nicely just in the question before this. I think, we're as confident and perhaps even more confident in our AI division for two reasons. Number one, we, we have been successful in about 30% of our screening mammography cases, having our patients enroll in what is increasingly being recognized as a very valuable addition to the breast screening process. This is, since we're going direct to consumer, since there is no reimbursement for AI at this point in time, this is a different strategy than most anything that we've attempted in the past. Although our prior effort in this was also successful some 8 years ago, I think it was, when 2D mammography got converted to 3D mammography, and we had a similar process that we implemented to have patients pay for this before it was reimbursed. We expect a similar process to unfold here so that the direct-to-consumer, we hope, is just a stopgap here until it's adopted by not only more and more of the payers, but more and more employees, employers, I should say, that recognize this kind of wellness screening can certainly benefit them as well as their employees. I'd, I'd like to pivot on that, that while that's been... a slow learning process for us. What I don't think will be slow will be the generative AI side of the initiatives that we have already begun embarking on, that we think can be transformative in the way that radiology is practiced and managed. I think that, in some respects, may even become more important in the short term here, given a number of the issues, as I mentioned in my opening remarks, with difficulties that we have in the labor market. I think you'll see from us in upcoming quarters, more specifics about how these tools can be implemented. Perhaps one of the more exciting methods that the new AI tools on the generative side are capable of is that we don't have to rewrite everything all at one time. We can take specific core needs that we have, like our contact centers and scheduling and insurance verification, and focus on them as segments that we can layer on when they're ready, rather than have to retool the entire platform that we have. This is a huge difference from the way that we and others have operated in the past that give us a lot of enthusiasm about the impact that we can have on our operational processes here in the very near future. In fact, we hope that some of these may be implemented as early as the first quarter of 2024. I, I think what you'll hear more and more from us is the continued efforts that we make, not only in, in our breast screening program, but also in lung screening and prostate screening, as we become more comfortable with the self-pay and direct-to-consumer marketing, as, as well as the initiatives to take control of our operational processes through generative AI algorithms, to not only create efficiencies, but to create a better patient experience for all of our people that choose to get their scans done in the RadNet locations. Got it. Then maybe, Mark, last question for me. I mean, thank you for giving color on your view on reimbursement. Remind me, if, if I'm thinking this correctly, this is about the same level that you see in terms of proposed cuts every year. Am I right in thinking that Congress has stepped in to kind of, like, block or mitigate this over the last, you know, three or four years? Yes. This, we believe, is the result. The proposed cut is the result of a phase-in of the budget neutrality aspect of increasing the E&M codes that primary care docs and family practice medicine docs bill under, which occurred several years ago, and they've been phasing in this cut in not just radiology, but every specialty, you know, in order to pay for those E&M increases. We've faced this cut for the last few years. It was a little bit higher the last couple of years, but then was ultimately mitigated by this Appropriations Act that was passed in December of both December of last year and the December of the prior year. It was a bipartisan bill that was sponsored by two congressmen, one Republican, one Democrat, from both California and Indiana. This is Bera and Bucshon. A lot of our experts and lobbyists, you know, not only within radiology, but within healthcare in general, because remember, this cut is being faced not just by radiologists, being faced by everybody, that, you know, there's a lot of support to try to get these cuts, you know, either reversed or mitigated. You know, we, we, we have some level of confidence that again, this year, some of the proposed cuts here in the, in the, the Medicare communication that we, we got several weeks ago will likely be mitigated. Regardless of whether it's mitigated or not, and we're estimating the, the total impact to be $7 million-$9 million range in our revenue, we've got more than that in terms of, of reimbursement increases that have either already gone into place in 2023, that will increase our reimbursement in 2024, or that will be scheduled to go into place, both within our capitation contracts as well as our, our commercial contracts. Regardless, we're not overly concerned about this level of, of reimbursement cut, but we do have some level of optimism that part of the Medicare cut will be mitigated. Awesome. Thank you. Brian, let me. Yeah, Brian, let me add one other thing, which I'm sure you're aware of, which may make the drive away from hospitals even stronger than it is right now. As I'm sure you're, as you've seen, that the new, Hospital Outpatient Prospective Payment System has increased the reimbursement to hospitals for their Medicare patients, further widening, you know, the potential-... reimbursement that's paid to hospitals for the same services that we provide on an freestanding outpatient basis. I think, it's interesting to see that the very thing that has been a big driver in moving the patients away from hospitals into outpatient centers, which was primarily from the commercial payers in the extraordinary difference in reimbursement, is now being seen also on the Medicare side of it. In the times that we exist, with inflation and expenses going up, it'll be even more imperative for our patients to be very mindful of where they get their place of service. To, to that point, Brian, the HOPPS schedule now has over a 30% premium relative to the outpatient Medicare fee schedule, which makes no, no sense whatsoever, particularly because Medicare supposedly is interested in, you know, site neutrality, you know, with respect to its reimbursement. You know, the-- as, as this spread widens, I think you're gonna have more and more Medicare patients, particularly ones that have, you know, a 20% copay, copay, which is very typical in the Medicare fee-for-service landscape, start directing their business out of hospitals, just like the private payers and commercial insurance plans are doing. Got it. Thanks, guys. Thank you. Our next question today comes from Nathan Malicki with Raymond James. Please go ahead. Hey, got on, Nate here, stepping in for John. Just first on the labor environment, last we heard, contract labor costs were running at about 50% of last year's level. Any update on, on contract labor, and anything you can quantify there? Then just more broadly on the labor environment, has that and will that continue to improve in the second half and then in the foreseeable future? Sure. Hi, Nate. I'll, I'll take this one. What we've said in the first quarter, what we did say in the first quarter, is that our reliance on contract labor, as well as our reliance on paying our own employee base, overtime, is about at 50% of what it was last year. It's not that the cost of, of outside labor, you know, of these, of these staffing companies has gone down by 50%. It's just that we're relying less on them as we've become more successful in filling open positions. If you remember, our number of open positions hit its height in September of last year. Throughout last year, we were mightily struggling with filling, you know, staff at our facility, at the facility level and keeping our centers open long enough to service the heavy demand. We've been much more successful this year, and there has been some stabilization in general in the labor market, in being able to staff our centers appropriately to keep the centers open, to fill, you know, more of this backlog. It's not that the pricing has gone down, it's just our reliance on outside services has gone down. Got you. Thanks for that. Then, you know, just on seasonality here, is it safe to assume that this year features kind of similar trends as kind of pre-pandemic periods? Maybe, I don't know, 24%-25% of total EBITDA in 3Q, and then a bit of a step up there in 4Q? Well, we typically do see seasonality in our business. The first quarter tends to be our most challenged quarter, primarily for two reasons. First being winter weather conditions in the Northeast or in the United States, where roughly 35% of our business is. You know, we're, we're impacted by, you know, storms that close facilities or, you know, power lines going down, power outages, things of that nature. The second reason the first quarter is a little slower is that the reset of patient deductibles tends to create a phenomenon where patients utilize healthcare services less at the beginning of the year and then are more, more liberal with their spending as they move through their deductibles, you know, towards latter parts of the year. We tend to see the first quarter and the first half of the year a little lighter than what we see in the third and fourth quarters. Summer vacations tend to impact the second quarter. The fourth quarter, as patients have moved through deductibles, tends to be high utilization, a high utilization quarter, and then you also have higher utilization of mammography in the fourth quarter, which coincides with the October month, which is breast cancer awareness. I would expect all things being equal, though, although, you know, we can never really tell, that the second half of the year tends to be stronger than the first half, and 2023 should be no different. Awesome. Thanks. Just to squeeze in one more here. On the equity and earnings of joint ventures line, it looks like that came in lighter than our model, and it was about- $1.5 million this quarter, kind of a bit of a deviation from historical trends. Anything to read through there in terms of, you know, JV consolidation or just the overall JV strategy, and then just how to think about that line item moving forward? That's all I got. Thank you. Yeah. Yeah, nothing I can think of that would be, you know, a trend. You know, obviously, one quarter a trend doesn't make. I would expect that line to, to, to even out. I have to go back to see what impacted the quarter in that, in, in that respect at, at our unconsolidated JV levels, which is what, you know, what you're talking about in terms of equity and earnings. There's nothing that's gone on there that would make that sustainable, that change. Thank you. Our next question today comes from Yuan Zhi with B. Riley Securities. Please go ahead. Good morning. Congrats on another strong quarter, and thank you for taking our questions. First, a follow-up on Brian's question, maybe more for Mark. I noticed the same center volume year-over-year growth rate was 7.1% versus 9.3% last quarter. The overall volume growth was 11.4 versus 14% last quarter. This might be a repeat from the last question, but specifically for your 2023 guidance in your modeling assumptions, do you anticipate the volume growth in the second half to be similar to what you have observed in 2Q? It will be great if you can comment on what you have observed so far regarding the patient flow in July. Thank you. Sure, sure. thanks, Yuan. Nice to talk to you. You know, we have had very strong same-center performance for the first half of the year. We've always said, you know, historically, that we felt over the long run, given the, you know, the, the growth in the industry and our, our growth in our markets and taking share away from competitors, that we felt that we could sustainably grow in the 3%-5% same-store sales growth over, you know, over the long period of time. As there has been significant growth, not only in the industry from some of the newer technologies such as, you know, PSMA, that Dr. Berger spoke about on the prostate side and other things that are driving new applications and new indications for ordering these tests. The industry's been growing nicely, and, and we've been growing faster because we're, we're also benefiting from the shift in hospital-based... from, from hospital-based, outpatient imaging to freestanding center imaging. Our growth over the last, you know, year or two has been exceeding that kind of 3%-5% range that we've talked about. In the first quarter, we had extraordinary growth, as you mentioned, at 9.3%, and we talked about it then, and I'll, I'll emphasize this now. We don't believe 9.3% is necessarily a sustainable number. We were impacted positively by two things in the first quarter that, you know, was extraordinary. The first being that we had a much more mild winter this year relative to, to the, the winter in the first quarter of 2022. That benefited us in the first quarter. The second extraordinary impact was that the first quarter of 2022 was impacted by the Omicron variant of COVID, where not only patients were impacted extensively, but, you know, our employee base was also impacted to the tune of having over 8% of our employee base on COVID leave, you know, for the first couple of weeks of January of last year. You know, the 9.3% was, this year in the first quarter, was better than it normally would have been, but for those two situations which I just described. The second quarter here was a much cleaner, what I'd call same-store sales comparison, with last year, where, you know, we weren't being impacted by weather, we weren't being impacted by Omicron in 2022. You know, it was, it was, I think, a more fair comparison. To your question directly about the second half of the year, you know, I would hope that, you know, we could exceed or be towards the high end of that 3%-5% growth, you know, same-store sales growth that we've, you know, talked about in the past. You know, would hope that it would look more like, you know, the, the, the second quarter going forward because of all the reasons that I've talked about, which is driving our growth. Got it. Maybe a quick follow-up there. If it would be great if you can comment on what you have observed so far, of the patient flow in July? July was a good month for us. July is always a bit of a challenge, given the July Fourth holiday and what day of the week it falls on, which this year it fell on a Tuesday, which is not necessarily most advantageous for us, given that the Monday is almost like an extension of the holiday weekend, and also the vacation schedule. Relative to last year's July volumes, we're pleased with the early results in July look like, and where August appears, at least for the first week, appears to be also holding, holding well with within our expectations. Got it. Thanks for the additional color there. Maybe Howard or Mark, can you provide more color on your capacity right now for MRI and PET scans? Are the current procedure close to your 90% of your capacity? I'm asking because, you know, the comments from Biogen, Eisai, they are targeting to treat 10,000 Alzheimer's disease patients by the end of March 2024. Assuming there is, you know, this increasing demand, I'm curious, what do you view as the rate-limiting factors for you to meet this demand, such as, you know, the numbers of imaging instruments you have, the staffing to support the procedure, or even the supply of imaging agent? Thank you. Great question. I'll be happy to answer that one. The demand that we have is not exceeding the capacity of our equipment. It's exceeding the ability of us to staff up to levels that allow us to use our equipment on the extended hours and times where we can see these patients. That's our biggest challenge, and it's particularly apparent in the MRI modalities. What we're doing to address that, which again, is somewhat novel to the RadNet core strategy and platform, is that there is new technology called remote operation command centers, that allow a technologist to operate more than one MRI equipment, piece of equipment remotely. What we have found is that in certain markets, for example, in Florida or in Arizona, where the shortage is not as serious as it is, let's say, in New York, we are gaining better acceptance and hiring of technologists that can run those systems remotely from other of our markets. That is probably the near-term ability for us to address some of these additional capacity issues. As Mark mentioned, we're also building more centers to add capacity, and in some cases, we have begun to buy our own mobile scanners that allow us, particularly, more so on the West Coast, to move those around to areas that are being particularly challenged. We do have a lot of tools in the toolkit, not the least of which also is that the newer MRI scanners or upgrades that we can make to existing scanners, have had a remarkable impact on reducing the scan time, which for many of our MRIs, has been reduced from 20 minutes -30 minutes down to 10 minutes, or in some cases, even less, has allowed us to increase our throughput and capacity in that manner. There's a number of ways to address these problems, and all of it, by and large, is really driven by the use of technology, both from a artificial intelligence standpoint, and some of these other remote tools and other algorithms that just help us increase our capacity without necessarily having to increase our staffing. Yuan, I'll, I'll address the second part of your question, which was specifically about Alzheimer's imaging and what you're hearing out of Biogen and Lilly and others. You the initial PET CT, which is one of the key ways of detecting the presence of these amyloid plaques, which is necessary to get these patients onto, you know, the, the, the newer therapies that have come out by some of these pharmaceutical companies, that, you know, could be a huge opportunity for diagnostic imaging and obviously for us. With respect to capacity, which I think was the question that you had asked as it relates to Alzheimer's imaging, you know, we currently have 67 PET scanners that are doing, on average... Well, doing in total, 60,000 scans per year, give or take. When you do the math over 255 work days, each PET CT scanner that we have is doing less than 4 PET CTs per day. The rest of the day, those scanners are very busy doing routine CT work. If we had, if, if there were a flood of PET CT demand, you know, in relation to these Alzheimer's drugs, what we, we, what we would do was, is to utilize our existing PET CT capacity, and each PET CT, a busy PET CT can be doing 13 scans, 14 scans, 15 scans a day. We have a lot of PET CT capacity in our existing install base. The challenge we would have at that point is then moving routine CT work to either other scanners, expanding hours, or having to buy additional CT to take over that level of volume. We do have, you know, a fair bit of PET CT capacity, even within our own install base at this point. ... Scott, appreciate all the help for Carter there. Thank you. Thank you. Our next question today comes from Mitra Ramgopal with Sidoti. Please go ahead. Yes. Hi, good morning. Thanks for taking the questions. Most of mine have already been answered, but I just had a quick one in terms of the cash on the balance sheet in light of the equity raise. How should we think of the capital allocation priorities in terms of growing the company via M&A, de novos, investments in technology and personnel, versus maybe looking to reduce debt given the high interest rate environment? I would say, all of the above, might be the best way for me to answer that, Mitra. I think one of the benefits of the equity raise that we accomplished was giving us the opportunity to look at ways that we can deploy that capital in the best interest of the company's growth. As we, we said, you know, one of our shorter-term possibilities is the pay down of some of our debt, but given the company's projected cash flow for the rest of this year and next year, I think, you'll find that we'll be investing in the de novos, upgrading technology of existing equipment, replacing older equipment with newer equipment. We used to use, in the past, operating leases, as a way of minimizing the amount of cash outlay. We have essentially eliminated that and now are paying cash for virtually all of our capital equipment investments. I think that will also help our margins and help the growth of the company. Lastly, we are looking to use the capital we raised to invest in our new digital health initiatives, which we think may have the best returns on investment, given the long-term prospects that we're tending towards a capital-light business that can have substantially better margins than the imaging center sector. We'll, we'll, we'll look to continue to utilize our capital in any way that can help the business grow. We'll look forward to discussing some of those with more detail, as the rest of this year unfolds. When we completed- when we completed the equity offering, because you can imagine, prospective investors were very interested in this very question. You know, what we said was, part of the reason why we're raising the money was that, in October of this year, one of our interest rate swaps roll off, and gives us more exposure to floating rate debt. We, we intend... And, and that's a, that's a $100 million of notional exposure that rolls off in October of this year. Our intention is to take $100 million from our cash balance at that time and repay debt so that we don't have more floating rate exposure. That's still our intention, to do that. The only reason why we wouldn't do that is if there were some extraordinary use of proceeds before that time, like a, like a M&A opportunity that would, you know, take its place. And, and, and that's not the intention in terms of utilizing it for M&A at this point. There's nothing that's a foregone conclusion. Okay, thanks. Congrats on a great quarter again. Thanks, Mitra. Thank you. Thank you. Ladies and gentlemen, this concludes our question and answer session. I'd like to turn the conference back over to the management team for any final remarks. Again, I would like to take this opportunity to thank all of our shareholders for their continued support, and the employees of RadNet for their dedication and hard work. Management will continue its endeavor to be a market leader that provides great services with an appropriate return on investment for all stakeholders. Thank you for your time today, and I look forward to our next call. Good day. Thank you, sir. This concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.